Search results
Earnings call: Verona Pharma reports Q1 2024 results, eyes COPD market By Investing.com
Investing.com· 4 hours agoVerona Pharma (NASDAQ:VRNA) has announced its first quarter 2024 financial results, highlighting the...
How Workplaces Can Contribute to COPD Risk
The Daily Advance· 2 days ago(StatePoint) Chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema, is a long-term ...
Pulmonary Function Test
Health via Yahoo News· 13 hours agoPurpose Pulmonary function tests are important for diagnosing and managing respiratory conditions that affect your lungs and/or airways, such as asthma...
New study links burn pits to higher respiratory and cardiovascular disease in veterans
NBC 10 Providence· 2 days agoNew research is showing a clearer cause and effect for many veterans. Burn pits were largely...
ProAxsis awarded Innovate UK grant for respiratory monitoring
Medical Device Network via Yahoo Finance· 14 hours agoThe plan is to integrate NEATstik and other respiratory health measures into a remote patient...
How a common diabetes drug may help prolong our health- and lifespan
Medical News Today· 3 days agoMetformin is an oral prescription drug widely used to control blood sugar in type 2 diabetes....
Yupelri Dosage: Form, Strength, How To Use, and More
Healthline· 3 days agoYupelri (revefenacin) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). The ...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 12 hours agoThe company is working on a drug to treat liver fibrosis due to hepatitis B and metabolic...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 days agoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript May 6, 2024 Enanta...
H.C. Wainwright drops Enanta Pharmaceuticals shares target on RSV program progress By Investing.com
Investing.com· 2 days agoOn Wednesday, H.C. Wainwright adjusted its price target on Enanta Pharmaceuticals (NASDAQ:ENTA)...
